Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR2 rearrangement

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

FoundationOne® CDx (110)

FoundationOne® CDx (110)

FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	FGFR inhibitor Sensitive: C3 – Early Trials FGFR inhibitor Sensitive : C3	FGFR inhibitor Sensitive: C3 – Early Trials FGFR inhibitor Sensitive : C3
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	RLY-4008 Sensitive: C3 – Early Trials RLY-4008 Sensitive : C3	RLY-4008 Sensitive: C3 – Early Trials RLY-4008 Sensitive : C3
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3	ICP-192 Sensitive: C3 – Early Trials ICP-192 Sensitive : C3
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	TT-00420 Sensitive: C3 – Early Trials TT-00420 Sensitive : C3	TT-00420 Sensitive: C3 – Early Trials TT-00420 Sensitive : C3